- Home
- SKIN vs SGMT Comparison
SKIN vs SGMT Comparison
Compare SKIN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKIN | SGMT |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.8M | 204.2M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SKIN | SGMT |
|---|---|---|
| Price | $1.55 | $6.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $2.00 | ★ $29.71 |
| AVG Volume (30 Days) | 347.1K | ★ 504.2K |
| Earning Date | 03-11-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $301,917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $1.73 |
| 52 Week High | $2.69 | $11.41 |
Technical Indicators
Market Signals| Indicator | SKIN | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 53.90 |
| Support Level | $1.41 | $5.95 |
| Resistance Level | $1.65 | $6.42 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 67.27 | 77.04 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.